)
AtriCure (ATRC) investor relations material
AtriCure Stifel 2026 Healthcare Conference 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Outlook and investment
2026 revenue guidance set at $606M-$610M; the lower implied Q4 growth rate reflects prudent conservatism, with international and U.S. hybrid business cited as potential headwinds.
The 2028 long-range plan targets $750M revenue and 14% adjusted EBITDA margin; management cited continued mid-teens revenue growth and catalysts that could support further outperformance.
Manufacturing expansion will effectively double production capability; facility costs may weigh on near-term gross margin before capacity is fully utilized, while newer products support high margins.
Investment is increasing in R&D and new product development while profitability progress continues; transformational M&A is not a current focus.
Quality metric and BoxX
STS quality metric rollout starts with a 70% goal and is expected to rise toward 90%+ over time; 2027 is expected to focus on awareness and reporting, with twice-yearly harvest periods.
STS will assess sites, with results also broken down by surgeon; the metric is expected to promote both appendage management and ablation, as the combined procedures provide benefits.
BoxX targets post-op AFib, which management cited at 35%-55% in controlled settings; trial endpoints assess 30-day post-op AFib and AFib burden over three years.
BoxX enrollment is expected to finish by year-end 2026; the 30-day endpoint is planned for May 2027, while the three-year endpoint will take longer to mature.
A 10 percentage-point absolute reduction in post-op AFib is considered clinically relevant; BoxX may have greater 2027 potential than the quality metric, though aggressive marketing awaits FDA labeling.
Products and clinical pipeline
A 30 mm FLEX-Mini clip is expected to launch in late 2026 after FDA clearance; FLEX-Mini V is in development, with clearance and launch expected in late 2027.
Edwards’ ECLIPTIS device is being introduced in the field, but management reported little headwind to date and emphasized its product, evidence base and experienced field team.
LEAPS enrolled in July 2025 and has reached 50% of its 469 events; the 75% event milestone is anticipated in 2028, potentially before the original five-year expectation.
- Revenue grew 20.8% in FY 2023 as adjusted EBITDA turned positive.ATRC
Q4 2023 - EnCompass-led adoption and expanding pain uses support growth, with a long-term adjusted EBITDA margin target above 20%.ATRC
UBS Global Healthcare Conference - Revenue grew, but losses and FDA dependence kept growth prospects high-risk.ATRC
Q4 2006 - Revenue grew 26.3%, while FDA approval and clinical progress remained pivotal.ATRC
Q4 2007 - Revenue grew, losses narrowed, and cost reductions targeted adjusted EBITDA breakeven.ATRC
Q4 2008 - Positive operating cash and new product launches contrasted with a wider FY09 net loss.ATRC
Q4 2009 - AtriClip launch and improving results advanced growth, while FDA and reimbursement risks remained.ATRC
Q4 2010 - FDA approval and international growth advanced the outlook, while margins fell and losses widened.ATRC
Q4 2011 - Revenue grew 9.1%, while losses widened; training and international expansion underpin FY13 plans.ATRC
Q4 2012
)
)
)
)
)
)
)
)